Evidence map›Paper›PMID 32569165›Full record

ArticleMedicine2020

Primary hyperoxaluria Type 1: A case report in an extended family with a novel AGXT gene mutation.

Mohamed W Abukhatwah, Samia H Almalki, Mohammed S Althobaiti, Abdulla O Alharbi, Najla K Almalki, Naglaa M Kamal

Open access · goldAbstract readCase Reports
In one paragraph

Article in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Mohamed W AbukhatwahPediatric department, Alhada Armed Forces Hospital.
Samia H AlmalkiPediatric department, Alhada Armed Forces Hospital.
Mohammed S AlthobaitiPediatric department, Alhada Armed Forces Hospital.
Abdulla O AlharbiPediatric department, Alhada Armed Forces Hospital.
Najla K AlmalkiNephrology department, Alhada Armed Forces Hospital, Taif, KSA.
Naglaa M KamalFaculty of Medicine, Cairo University, Cairo, Egypt.ORCID 0000-0002-8535-3838
Armed Forces Hospital · SACairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPrimary hyperoxaluria type 1 (PH1) is a genetic autosomal recessively inherited disorder due to mutation in the alanine-glyoxylate aminotransferase (AGXT) gene. It usually presents in children with nephrolithiasis and/or nephrocalcinosis and progressive renal function impairment and end stage renal disease (ESRD). PATIENT CONCERNS: A 13 years old Saudi boy with history of recurrent urolithiasis since the age of 2 years presented to us with picture of ESRD. He has strong family history of urolithiasis. DIAGNOSIS: Working up the patient suggested the diagnosis of PH1 based on the typical clinical, laboratory, and imaging findings which was genetically proved by positive AXGT gene mutation. The mutation detected was not previously reported in literature. The mutation detected was not previously reported in literature. The novel mutation c. 799A>T p. (IIe267Phe) detected in our patient extend the spectrum of the known AGXT gene mutations. INTERVENTIONS AND OUTCOMES: Hemodialysis as a temporary step followed by renal transplantation which is the only cure.

conclusionHigh index of suspicion of PH1 before ESRD should be considered in any patient who has recurrent urolithiasis since early life especially in presence of strong family history.

Indexed as

AdolescentHumansHyperoxaluria, PrimaryMaleTransaminasesAlanine-glyoxylate transaminaseTransaminases

Identifiers

PMID32569165
PMCPMC7310847
OpenAlexW3036954764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.